Tempus AI (TEM) shares fell sharply by 5.87% during intraday trading on Tuesday, following a significant target price reduction by a major financial institution.
The decline came after Morgan Stanley cut its price target for Tempus AI to $70.00 from $85.00, representing a substantial downward revision in the bank's valuation of the company.
While Tempus AI also announced a strategic, multi-year collaboration with Merck to accelerate AI-driven precision medicine, the negative impact of the analyst target price cut appears to have outweighed the positive collaboration news in today's trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments